GET DAILY SIGNALSAnaptysBio (ANAB) Earnings Preview: First Look at the New Royalty-Focused Model
Key Takeaways
- AnaptysBio is set to report results for the first quarter of fiscal year 2027 (the three months ended September 30, 2026), its first full quarter under a newly adopted June 30 fiscal year-end.
- Consensus estimates tracked by Zacks point to earnings of about $0.41 per share on revenue near $32.1 million, down from $76.3 million a year earlier, when results benefited from a large one-time item.
- The company now operates as a royalty management business, centered on the Jemperli (dostarlimab) royalty stream with GSK and the imsidolimab collaboration with Vanda Pharmaceuticals.
- Jemperli momentum remains a key driver, with GSK reporting roughly $331 million in second-quarter 2026 global sales, up 26% year over year.
- The dominant overhang is a pending ruling in AnaptysBio's breach-of-contract lawsuit against GSK and Tesaro, expected in the fourth quarter of 2026 or first quarter of 2027.
- The company held $164.1 million in cash and investments as of June 30, 2026, with a $100 million share repurchase plan still unutilized ahead of its December 31, 2026 expiration.
Why This Earnings Report Matters
This report marks ANAB's first full quarter as a pure royalty management company following the April 2026 separation of its clinical-stage assets into First Tracks Biotherapeutics. Investors will look for evidence that the streamlined model can sustain collaboration revenue growth while containing the general and administrative (G&A) costs that spiked during the transition and ongoing litigation. The quarter also arrives in the shadow of a potentially transformative court decision over ANAB's Jemperli royalty rights with GSK, making management's commentary on the litigation timeline and royalty trajectory as closely watched as the headline numbers themselves. From what I see, I also checked this using Tickeron’s AI Screener to compare the royalty profile against peers.
What Analysts Are Expecting
Analysts tracked by Zacks expect ANAB to report earnings of approximately $0.41 per share for the September 2026 quarter, representing a year-over-year decline of about 21%. Revenue is projected near $32.09 million, down roughly 58% from the prior-year period, when the top line was inflated by a one-time benefit. Other data providers show a wider range, reflecting the inherent lumpiness of royalty and collaboration revenue recognition.
For context, ANAB last reported a loss of $0.11 per share for the quarter ended June 30, 2026, beating the consensus estimate of a $0.46 loss by 76%. The company has beaten consensus earnings estimates in three of the last four quarters, though its history includes both large beats and a substantial miss tied to separation-related costs. Beyond the income statement, investors will monitor collaboration revenue from Jemperli royalties, the trend in G&A expenses, the cash position, and any updates on the GSK litigation and the rectal cancer program.
Market Reaction and Investor Sentiment
Sentiment heading into the report remains broadly constructive but cautious. Analyst coverage is heavily bullish, with 10 "Strong Buy" ratings and one "Hold" among 11 analysts, and an average price target near $86.80, according to data cited around the prior release. However, the unresolved GSK litigation has created a "wait-and-see" dynamic, and sentiment has softened modestly over the past month as investors await clarity. One thing that stands out is how the stock may react more to litigation commentary and royalty guidance than to a single quarter's top-line figure.
Forward Outlook and Key Factors to Monitor
The most consequential near-term catalyst is the Delaware Chancery Court ruling in ANAB's breach-of-contract case against GSK and Tesaro. A post-trial hearing was held on October 20, 2026, and the company anticipates a judgment in the fourth quarter of 2026 or first quarter of 2027. ANAB is seeking reversion of its Jemperli rights as a remedy, a move that could substantially reshape the company's value proposition. Separately, investors should track the commercial trajectory of Jemperli. Positive interim results from the pivotal AZUR-1 trial in mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer were announced in July, and the U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of February 2027, with the possibility of an expedited decision.
On the financial side, watch whether G&A spending normalizes now that separation-related costs are receding, and whether management deploys the $100 million repurchase plan before its December 31, 2026 expiration. With $164.1 million in cash and investments as of June 30, 2026, capital allocation choices will remain in focus as the company settles into its new fiscal-year reporting cadence. I’m watching this closely, and I also checked this using Tickeron’s AI Trend Prediction Engine to gauge potential royalty momentum.
Using Tickeron Tools in My Research
In my research process, I frequently rely on Tickeron’s AI Screener to filter stocks by fundamentals, technical patterns, and AI-driven signals. It helps me quickly identify how ANAB stacks up against similar royalty-focused names and spot any emerging trends in the biotech space without spending hours on manual analysis. This kind of tool complements traditional earnings previews by highlighting comparable opportunities or risks that might otherwise be overlooked.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ANAB's RSI Indicator recovers from oversold territory
The RSI Indicator for ANAB moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 17 of the 21 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 220 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 62 cases where ANAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANAB as a result. In 82 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ANAB entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ANAB's P/B Ratio (110.017) is very high in comparison to the industry average of (3.104). P/E Ratio (-45.990) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of therapeutic antibodies for inflammation and immuno-oncology
Industry Biotechnology
Advertisement